52395-99-0 Usage
General Description
Belarizine is a dopamine D2 receptor antagonist that is used as an antipsychotic medication. It is known by the brand name "Anquil" and is primarily used in the treatment of schizophrenia and other psychotic disorders. Belarizine works by blocking the effects of dopamine in the brain, which helps to reduce the symptoms of psychosis such as hallucinations and delusions. It is also being studied for its potential use in the treatment of bipolar disorder and depressive disorders. Belarizine is typically administered in tablet form and its use is associated with potential side effects such as sedation, weight gain, and movement disorders. As with any medication, it is important to consult with a healthcare professional to determine if Belarizine is the right treatment option for an individual's specific condition.
Check Digit Verification of cas no
The CAS Registry Mumber 52395-99-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,3,9 and 5 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 52395-99:
(7*5)+(6*2)+(5*3)+(4*9)+(3*5)+(2*9)+(1*9)=140
140 % 10 = 0
So 52395-99-0 is a valid CAS Registry Number.
InChI:InChI=1/C24H26N2O/c27-23-13-11-20(12-14-23)19-25-15-17-26(18-16-25)24(21-7-3-1-4-8-21)22-9-5-2-6-10-22/h1-14,24,27H,15-19H2
52395-99-0Relevant articles and documents
New serine protease inhibitors with leukotriene B4 (LTB4) receptor binding affinity
Nakayama, Yoshisuke,Senokuchi, Kazuhiko,Sakaki, Katsuhito,Kato, Masashi,Maruyama, Toru,Miyazaki, Toru,Ito, Hidenori,Nakai, Hisao,Kawamura, Masanori
, p. 971 - 985 (2007/10/03)
A series of new trypsin-like serine protease inhibitors, 1, 2 and 7-23, containing amidinobenzene moiety was found to show potent LTB4-receptor affinity. Among them, compounds 1 and 2 were found to be LTB4 receptor antagonists based on an inhibition assay of human polymorphonuclear neutrophil (PMN) intracellular calcium mobilization induced by LTB4. Compounds 1 and 2, which satisfy the reported structural requirements for good oral activity, are expected to show a balanced dual mode of action, i.e., protease inhibitory activity and LTB4 receptor antagonist activity, in vivo.
